Considering that IL‐36γ and IL‐36Ra are the major IL‐36 cytokines in the lung tumors and that IL‐36Ra antagonizes IL‐36γ‐triggered signaling by competitively binding to IL‐36R (Figure S2D,E, Supporting Information),[38] we reasoned that IL‐36Ra might antagonize the effects of IL‐36γ on promotion of NSCLC progression. The gene discussed is IL36G; the disease is non-small cell lung carcinoma.